About

Veronica Shi, M.D., is an Assistant Clinical Professor in the Department of Dermatology at UC San Diego. Her research and clinical work focus on dermatological conditions, including skin manifestations related to cancer therapies and immune checkpoint inhibitors. She has contributed to the understanding of cutaneous adverse effects of various treatments, such as immune checkpoint inhibition, targeted chemotherapies, and anti-vascular endothelial growth factor agents. Her publications include case reports and studies on conditions like Merkel cell carcinoma, leukocytoclastic vasculitis, lichenoid mucocutaneous eruptions, and other skin-related manifestations of systemic diseases and treatments. Dr. Shi's work involves both clinical practice and research, with a particular interest in the dermatologic side effects of cancer immunotherapies and targeted treatments.

Research topics

• Medicine
• Internal medicine
• Gastroenterology
• Surgery

Selected publications

• Merkel cell carcinoma with concurrent squamous cell carcinoma of the lower lip treated with Mohs micrographic surgery: A case report

  JAAD Case Reports · 2024-10-02

  articleOpen access
  PublisherOA PDFDOI

• Chronic Progressive Pink-Yellow Papules and Nodules in a Middle-Aged Man

  JAMA Dermatology · 2024-04-17 · 1 citations

  articleSenior author

  A 38-year-old man presented with numerous pink-yellow firm papules and nodules on the bilateral elbows for 10 years spreading to the hands and knees in the past year. What is your diagnosis?

  PublisherDOI

• Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma

  ONCOLOGY · 2022 · 8 citations

  • Medicine
  • Internal medicine
  • Gastroenterology

  A Mexican woman, aged 60 years, presented with fevers and abdominal pain. She had initially presented to an outside emergency department with weakness, malaise, nausea, vomiting, tachycardia to 110s, and fever to 102 °F. Her medical history was relevant for hypertension, prediabetes, and tobacco use (4-5 cigarettes/day for 12 years). There was no significant family history. Pertinent labs included hemoglobin 8.0 g/dL, white blood cells 13.1 × 109/L, absolute neutrophil count 10.2 × 109/L, creatinine 1.3 mg/dL, calcium 9.2 mg/dL, and lactate dehydrogenase 682 U/L. Initial imaging showed a large 14-cm right renal mass, with tumor in vein in the right renal vein and inferior vena cava, and extensive bilateral pulmonary emboli. A pulmonary thrombectomy was performed, with pathology on the right lung thrombus consistent with metastatic clear cell renal cell carcinoma (RCC), cT4N0M1, categorized as intermediate risk per the International Metastatic RCC Database Consortium.

  DOI

• Epidemiology and Screening of Pigmented Lesions

  2018-06-14

  book-chapter1st authorCorresponding
  PublisherDOI

• Cyanosis of the foot.

  PubMed · 2017-10-01 · 1 citations

  article1st authorCorresponding
  Publisher

• The Melanoma Handbook

  2017-04-01 · 2 citations

  book
  PublisherDOI

• Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

  JAMA Dermatology · 2016-07-13 · 238 citations

  articleOpen access1st author

  Importance: Antagonist antibodies to programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have shown remarkable activity in multiple tumor types. Recent US Food and Drug Administration approval of such agents for advanced melanoma, non-small cell lung cancer, and renal cell carcinoma has hastened the need to better characterize their unique toxicity profiles. Objective: To provide a clinical and pathologic description of the lichenoid mucocutaneous adverse effects seen in patients receiving anti-PD-1/PD-L1 treatment. Design, Setting, and Participants: Patients with advanced cancer who were referred to dermatology at Yale-New Haven Hospital, a tertiary care hospital, after developing cutaneous adverse effects while receiving an anti-PD-1 or PD-L1 antibody therapy either as monotherapy or in combination with another agent were identified. Medical records from 2010 to 2015 and available skin biopsy specimens were retrospectively reviewed. Main Outcomes and Measures: Patient demographic characteristics, concurrent medications, therapeutic regimen, type of disease, previous oncologic therapies, clinical morphology of cutaneous lesions, treatment of rash, peripheral blood eosinophil count, tumor response, and skin histologic characteristics if biopsies were available. Results: Patients were 13 men and 7 women, with a mean (range) age of 64 (46-86) years. The majority of cases (16 [80%]) had a clinical morphology consisting of erythematous papules with scale in a variety of distributions. Biopsies were available from 17 patients; 16 (94%) showed features of lichenoid interface dermatitis. Eighteen patients were treated with topical corticosteroids, and only 1 patient required discontinuation of anti-PD-1/PD-L1 therapy. Only 4 of 20 patients (20%) developed peripheral eosinophilia. Sixteen patients (80%) were concurrently taking medications that have been previously reported to cause lichenoid drug eruptions. Conclusions and Relevance: Papular and nodular eruptions with scale, as well as mucosal erosions, with lichenoid features on histologic analysis were a distinct finding seen with anti-PD-1/PD-L1 therapies and were generally manageable with topical steroids. Concurrent medications may play a role in the development of this cutaneous adverse effect.

  PublisherOA PDFDOI

• Cutaneous manifestations of nontargeted and targeted chemotherapies

  Seminars in Oncology · 2016-02-24 · 30 citations

  review1st author
  PublisherDOI

• Clinical And Histologic Features Of Cutaneous Toxicities Due To Anti-Programmed Cell Death-1 Therapy

  2016-01-01

  article1st authorCorresponding
  Publisher

• Cutaneous Vasculopathy as an Adverse Effect of the Anti–Vascular Endothelial Growth Factor Agent Axitinib

  JAMA Dermatology · 2015-10-28 · 7 citations

  article1st authorCorresponding

  AxitinibAxitinib is a targeted chemotherapeutic agent against the vascular endothelial growth factor (VEGF) receptor pathway.Cutaneous toxic effects of these newer targeted therapies are increasingly being recognized.Herein we present a case of cutaneous vasculopathy associated with axitinib.

  PublisherDOI

Frequent coauthors

• Brian Hinds

  11 shared

• Gastrointestinal Cancer

  Clarke University

  9 shared

• Joe Petroziello

  Thomas Jefferson University Hospital

  9 shared

• Los Ángeles

  New York Proton Center

  9 shared

• Stephen M. Schleicher

  DermDox Dermatology Centers

  9 shared

• Kristie L. Kahl

  Clarke University

  9 shared

• Richard A. Drachtman

  Rutgers Cancer Institute of New Jersey

  9 shared

• Ceo

  Clarke University

  9 shared

Education

• M.D.

  University of California, San Diego

  2006

• B.S.

  University of California, San Diego

  2002